Literature DB >> 12818412

Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease.

Sung-Joon Lee1, Lemuel A Moye, Hannia Campos, Gordon H Williams, Frank M Sacks.   

Abstract

High apoCIII concentration in apoB lipoproteins is a prominent component of atherogenic dyslipidemia, and explains the risk of coronary heart disease (CHD) associated with high triglyceride (TG). We hypothesized that diabetic people have atherogenic dyslipidemia with apoCIII in excess of that accounted for by their high TG levels. We selected 30 diabetic and 30 nondiabetic persons, 15 of each with fasting TG<160 mg/dl and 15 with TG>/=200 mg/dl. Using immunoaffinity chromatography and ultracentrifugation, we prepared large and small VLDL, IDL and LDL with or without apoCIII or apoE. The groups with TG>/=200 mg/dl, regardless of diabetes status, had higher concentrations of large and small VLDL particles with apoCIII and higher apoCIII concentrations than the groups with fasting TG<160 mg/dl. The diabetes groups did not have higher concentrations of these lipoproteins than the nondiabetes groups within the same fasting TG criteria. In conclusion, high concentrations of apoCIII-containing VLDL are associated with hypertriglyceridemia, which may play a critical role in identifying the high risk of CHD in hypertriglyceridemic patients whether diabetic or nondiabetic. Diabetes status per se does not appear to be associated with high concentrations of apoCIII-containing TG-rich lipoprotein particles, if the plasma TG levels are similar.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818412     DOI: 10.1016/s0021-9150(03)00007-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

2.  Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Sarah A Aroner; Jeremy D Furtado; Frank M Sacks; Michael Y Tsai; Kenneth J Mukamal; Robyn L McClelland; Majken K Jensen
Journal:  Diabetologia       Date:  2019-04-04       Impact factor: 10.122

Review 3.  Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Anton Stalenhoef
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-10-17       Impact factor: 4.690

4.  Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

Authors:  Anne Hiukka; Jamila Fruchart-Najib; Eeva Leinonen; Hannele Hilden; Jean-Charles Fruchart; Marja-Riitta Taskinen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

5.  RNA-seq analysis provide new insights into mapk signaling of apolipoproteinciii-induced inflammation in porcine vascular endothelial cells.

Authors:  Yuan Yue; Hao Jiang; Shouqing Yan; Yao Fu; Chang Liu; Xulei Sun; Menglong Chai; Yan Gao; Bao Yuan; Chengzhen Chen; Lisheng Dai; Jiabao Zhang; Yu Ding
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

6.  Presence of apolipoprotein C-III attenuates apolipoprotein E-mediated cellular uptake of cholesterol-containing lipid particles by HepG2 cells.

Authors:  Shin-ya Morita; Atsushi Sakurai; Minoru Nakano; Shuji Kitagawa; Tetsurou Handa
Journal:  Lipids       Date:  2010-11-16       Impact factor: 1.880

7.  Significance of Lipid Profile Parameters in Predicting Pre-Diabetes.

Authors:  O H Jasim; M M Mahmood; A H Ad'hiah
Journal:  Arch Razi Inst       Date:  2022-02-28

Review 8.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

9.  HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: A Multicenter Cohort Study.

Authors:  Rain Yamamoto; Majken K Jensen; Sarah Aroner; Jeremy D Furtado; Bernard Rosner; Frank B Hu; Beverley Balkau; Andrea Natali; Ele Ferrannini; Simona Baldi; Frank M Sacks
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.